2. Academic Validation
  3. Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia

Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia

  • J Med Chem. 2021 Sep 9;64(17):12603-12629. doi: 10.1021/acs.jmedchem.1c00497.
Monika Marcinkowska 1,  Adam Bucki 1,  Joanna Sniecikowska 1,  Agnieszka Zagórska 1,  Nikola Fajkis-Zajączkowska 1,  Agata Siwek 1,  Monika Gluch-Lutwin 1,  Paweł Żmudzki 1,  Magdalena Jastrzebska-Wiesek 1,  Anna Partyka 1,  Anna Wesołowska 1,  Michał Abram 1,  Katarzyna Przejczowska-Pomierny 1,  Agnieszka Cios 1,  Elżbieta Wyska 1,  Kamil Mika 1,  Magdalena Kotańska 1,  Paweł Mierzejewski 2,  Marcin Kolaczkowski 1 3
Affiliations

Affiliations

  • 1 Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Krakow, Poland.
  • 2 Institute of Psychiatry and Neurology, 9 Sobieskiego Street, 02-957 Warsaw, Poland.
  • 3 Adamed Pharma S.A., 6A Mariana Adamkiewicza Street, Pienkow, 05-152 Czosnow, Poland.
PMID: 34436892 DOI: 10.1021/acs.jmedchem.1c00497
Abstract

The current pharmaceutical market lacks therapeutic agents designed to modulate behavioral disturbances associated with dementia. To address this unmet medical need, we designed multifunctional ligands characterized by a nanomolar affinity for clinically relevant targets that are associated with the disease pathology, namely, the 5-HT2A/6/7 and D2 receptors. Compounds that exhibited favorable functional efficacy, water solubility, and metabolic stability were selected for more detailed study. Pharmacological profiling revealed that compound 11 exerted pronounced antidepressant activity (MED 0.1 mg/kg), outperforming commonly available antidepressant drugs, while compound 16 elicited a robust anxiolytic activity (MED 1 mg/kg), exceeding comparator anxiolytics. In contrast to the existing psychotropic agents tested, the novel chemotypes did not negatively impact cognition. At a chronic dose regimen (25 days), 11 did not induce significant metabolic or adverse blood pressure disturbances. These promising therapeutic-like activities and benign safety profiles make the novel chemotypes potential treatment options for dementia patients.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z